Kenvue Inc. (NYSE:KVUE) Shares Bought by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. raised its position in Kenvue Inc. (NYSE:KVUE) by 2.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 36,691 shares of the company’s stock after purchasing an additional 737 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Kenvue were worth $668,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after acquiring an additional 25,238,112 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Kenvue by 12.0% during the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after acquiring an additional 17,908,497 shares during the last quarter. Norges Bank acquired a new stake in shares of Kenvue during the fourth quarter valued at $282,100,000. Van ECK Associates Corp lifted its position in Kenvue by 110.9% during the second quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock worth $372,880,000 after buying an additional 10,783,258 shares during the period. Finally, Clearbridge Investments LLC lifted its position in Kenvue by 16,051.1% during the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock worth $210,600,000 after buying an additional 9,752,836 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $23.39 on Wednesday. The company has a market cap of $44.79 billion, a P/E ratio of 29.99, a PEG ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.55. The business’s 50-day simple moving average is $20.62 and its 200 day simple moving average is $19.88.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The business had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s revenue was down .3% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were issued a dividend of $0.205 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft increased their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Citigroup reduced their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of Kenvue in a research report on Wednesday, August 7th. UBS Group raised their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. raised their price objective on Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.44.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.